Varlilumab (INN;[1] development code CDX-1127) is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies.[2] It is an anti-CD27 antibody and helps activate T-cells.[3]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | CD27 |
| Clinical data | |
| Other names | CDX-1127 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6486H9992N1740O2022S42 |
| Molar mass | 146043.96 g·mol−1 |
This drug was developed by Celldex Therapeutics.
It (in combination with ONT-10) has undergone a phase 1B clinical trial for advanced breast or ovarian cancer.[4] In combination with anti-PD-1 nivolumab it has undergone a phase 1/2 trial for advanced refractory solid tumours[5]
References
edit- ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Varlilumab, American Medical Association.
- ^ Melão A (June 2017). "Varlilumab-Opdivo Combo Stabilizes or Shrinks Tumors in 80% of Solid-cancer Patients, Trial Shows".
- ^ Clinical trial number NCT02270372 for "Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer" at ClinicalTrials.gov
- ^ Clinical trial number NCT02335918 for "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |